|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0282461,
umls-concept:C0308269,
umls-concept:C0684249,
umls-concept:C0817096,
umls-concept:C1274040,
umls-concept:C1517927,
umls-concept:C1518419,
umls-concept:C1522449
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1998-3-25
|
|
pubmed:abstractText |
A three-arm Phase III randomized trial was performed to compare response rates, time to local or distant progression, and survival for patients with unresectable (Stage IIIA or IIIB) nonsmall cell lung carcinoma treated with standard fractionated thoracic radiotherapy (SFTRT) versus accelerated hyperfractionated thoracic radiotherapy (AHTRT) with or without combination etoposide and cisplatin chemotherapy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1037-48
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9506347-Adult,
pubmed-meshheading:9506347-Aged,
pubmed-meshheading:9506347-Aged, 80 and over,
pubmed-meshheading:9506347-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9506347-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:9506347-Cisplatin,
pubmed-meshheading:9506347-Combined Modality Therapy,
pubmed-meshheading:9506347-Disease Progression,
pubmed-meshheading:9506347-Dose Fractionation,
pubmed-meshheading:9506347-Etoposide,
pubmed-meshheading:9506347-Female,
pubmed-meshheading:9506347-Humans,
pubmed-meshheading:9506347-Infusions, Intravenous,
pubmed-meshheading:9506347-Lung Neoplasms,
pubmed-meshheading:9506347-Male,
pubmed-meshheading:9506347-Middle Aged,
pubmed-meshheading:9506347-Neoplasm Recurrence, Local,
pubmed-meshheading:9506347-Radiotherapy Dosage,
pubmed-meshheading:9506347-Survival Analysis,
pubmed-meshheading:9506347-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.
|
|
pubmed:affiliation |
Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
